Evidence map›Paper›PMID 40172651›Full record

GuidelineZeitschrift fur Rheumatologie2025

[Diagnosis and treatment of ANCA-associated vasculitis : SHORT VERSION of the S3 guideline of the German Society for Rheumatology and Clinical Immunology e. V. (DGRh) and German Society for Internal Medicine e. V. (DGIM), German Society for Nephrology e. V. (DGfN), German Society for Otorhinolaryngology and Head and Neck Surgery e. V. (DGHNO-KHC), German Ophthalmological Society e. V. (DOG), German Society for Neurology e. V. (DGN), German Society for Pneumology and Respiratory Medicine e. V. (DGP), German Society for Pathology e. V. (DGP), German Radiological Society, Society for Medical Radiology e. V. (DRG), Federal Association of German Pathologists, Federal Kidney Association e. V., German Rheumatism League Federal Association e. V.]

J U Holle, T Kubacki, P Aries, B Hellmich, A Kernder, C Kneitz, P Lamprecht, J H Schirmer, A Schreiber, P Berlit and 24 more

Abstract readEnglish AbstractPractice Guideline
PubMed Publisher
In one paragraph

Guideline in Zeitschrift fur Rheumatologie, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors.

J U HolleRheumazentrum Schleswig-Holstein Mitte, Neumünster/Kiel, Deutschland. holle@rheuma-sh.de.
T KubackiKlinik für Innere Medizin II-Nephrologie, Rheumatologie, Diabetologie u. Allg. Innere Medizin, Universitätsklinikum Köln, Köln, Deutschland.
P AriesImmunologikum Hamburg, Hamburg, Deutschland.
B HellmichKlinik für Innere Medizin, Rheumatologie, Pneumologie, Nephrologie, Medius Kliniken Nürtingen/Esslingen, Deutschland.
A KernderRheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Bochum, Deutschland.
C KneitzRheumatologische Praxisgemeinschaft, Schwerin, Deutschland.
P LamprechtKlinik für Rheumatologie und Klinische Immunologie, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Deutschland.
J H SchirmerKlinik für Innere Medizin I, Sektion Rheumatologie und klinische Immunologie, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Deutschland.
A SchreiberMedizinische Klinik, Schwerpunkt Nephrologie, Charité Universitätsmedizin, Berlin, Deutschland.
P BerlitDeutsche Gesellschaft für Neurologie.
T A BleyInstitut für Diagnostische und Interventionelle Radiologie, Universitätsklinikum Würzburg, Würzburg, Deutschland.
S BlödtAWMF.
L DeckerMedizinisches Versorgungszentrum HNO Dormagen, Rheinland Klinikum, Dormagen, Deutschland.
K de GrootKlinik für Nephrologie und Rheumatologie, Sana Kliniken Offenbach, Offenbach, Deutschland.
S EngelDeutsche Rheuma-Liga Bundesverband e. V.
I JordansBundesverband Niere e. V.
B FryeDepartment Innere Medizin, Klinik für Pneumologie, Universitätsklinikum Freiburg, Freiburg, Deutschland.
M HaubitzMedizinische Klinik III (Nephrologie), Klinikum Fulda, Fulda, Deutschland.
K Holl-UlrichKonsultations- und Referenzzentrum für Vaskulitisdiagnostik, Labor Lademannbogen, Hamburg, Deutschland.
I KötterIII. Medizinische Klinik und Poliklinik, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Deutschland.
M LaudienKlinik für HNO-Heilkunde, Kopf- und Halschirurgie, Christian-Albrechts-Universität zu Kiel, Kiel, Deutschland.
K Milger-KneidingerMedizinische Klinik und Poliklinik V, Ludwig-Maximilians-Universität München, München, Deutschland.
C Muche-BorowskiAWMF.
U Müller-LadnerAbteilung für Rheumatologie und Klinische Immunologie, Justus-Liebig-Universität, Gießen, Campus Kerckhoff, Bad Nauheim, Deutschland.
T NeßKlinik für Augenheilkunde, Universitätsklinikum Freiburg, Freiburg, Deutschland.
B NölleKlinik für Ophthalmologie, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Deutschland.
E Reinhold-KellerMedizinicum Hamburg Nienstedten, Hamburg, Deutschland.
N RufferIII. Medizinische Klinik und Poliklinik, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Deutschland.
K ScheuermannDeutsche Rheuma-Liga Bundesverband e. V.
N VenhoffKlinik für Rheumatologie und Klinische Immunologie, Vaskulitis-Zentrum Freiburg, Medizinische Fakultät, Albert-Ludwigs-Universität Freiburg, Freiburg, Deutschland.
S von VietinghoffMedizinische Klinik und Poliklinik I, Sektion für Nephrologie, Universitätsklinikum Bonn und Universität Bonn, Bonn, Deutschland.
T WiechInstitut für Pathologie, Sektion Nephropathologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Deutschland.
M ZänkerKlinik für Innere Medizin, Rheumatologie, Nephrologie, Immanuel Klinikum Bernau, Medizinische Hochschule Brandenburg, Deutschland.
F MoosigRheumazentrum Schleswig-Holstein Mitte, Neumünster/Kiel, Deutschland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vasculitis associated with anti-neutrophil cytoplasmic antibodies (ANCA) is a rare disease with a potentially severe course. Affected patients should be diagnosed as quickly as possible and given suitable treatment according to the current study situation. Considerable progress has been made in the treatment of this disease in recent years, so that a largely evidence-based therapy with immunosuppressants and biologics is now possible. The guideline on the diagnosis and treatment of ANCA-associated vasculitis was raised from S1 level (2017) to S3 level. This guideline is the first German guideline on the diagnosis and treatment of ANCA-associated vasculitis at S3 level.

Indexed as

Allergy and ImmunologyAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisImmunosuppressive AgentsRheumatologyAntibodies, Antineutrophil CytoplasmicEvidence-Based MedicineGermanyHumansInternal MedicineAntibodies, Antineutrophil CytoplasmicImmunosuppressive AgentsAntigen-specific immunoassaysAnti-neutrophil cytoplasmic antibodyBiologicsImmunosuppressantsRecommendations

Identifiers

PMID40172651

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.